{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:06:32Z","timestamp":1784005592500,"version":"3.55.0"},"reference-count":37,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T00:00:00Z","timestamp":1522972800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0338-6","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T15:29:49Z","timestamp":1524151789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition"],"prefix":"10.1136","volume":"6","author":[{"given":"Zo\u00eb","family":"Blake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas K.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn D.","family":"Gartrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patti","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon K.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret","family":"Taback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil A.","family":"Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne M.","family":"Saenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,4,6]]},"reference":[{"key":"338_CR1","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517\u201326.","journal-title":"N Engl J Med"},{"key":"338_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"338_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908\u201318.","journal-title":"Lancet Oncol"},{"key":"338_CR4","doi-asserted-by":"crossref","first-page":"9505","DOI":"10.1200\/JCO.2016.34.15_suppl.9505","volume":"34","author":"JD Wolchok","year":"2016","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol. 2016;34:9505.","journal-title":"J Clin Oncol"},{"key":"338_CR5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1053\/j.seminoncol.2016.10.005","volume":"43","author":"C Grigg","year":"2016","unstructured":"Grigg C, Blake Z, Gartrell R, et al. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. Semin Oncol. 2016;43:638\u201346.","journal-title":"Semin Oncol"},{"key":"338_CR6","doi-asserted-by":"crossref","first-page":"9026","DOI":"10.1200\/jco.2014.32.15_suppl.9026","volume":"32","author":"MI Ross","year":"2014","unstructured":"Ross MI, Andtbacka RHI, Puzanov I, et al. Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): results from a phase III trial in patients with stage IIIb-IV melanoma. J Clin Oncol. 2014;32:9026.","journal-title":"J Clin Oncol"},{"key":"338_CR7","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","volume":"34","author":"I Puzanov","year":"2016","unstructured":"Puzanov I, Milhem MM, Minor D, et al. Talimogene Laherparepvec in combination with Ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34:2619\u201326.","journal-title":"J Clin Oncol"},{"key":"338_CR8","doi-asserted-by":"publisher","first-page":"9568","DOI":"10.1200\/JCO.2015.62.9345","volume":"34","author":"GV Long","year":"2016","unstructured":"Long GV, Dummer R, Ribas A, et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34:9568.","journal-title":"J Clin Oncol"},{"key":"338_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11940-017-0449-2","volume":"19","author":"AS Berghoff","year":"2017","unstructured":"Berghoff AS, Preusser M. Targeted therapies for melanoma brain metastases. Curr Treat Options Neurol. 2017;19:13.","journal-title":"Curr Treat Options Neurol"},{"key":"338_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976\u201383.","journal-title":"Lancet Oncol"},{"key":"338_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2016.07.003","volume":"65","author":"MC Kirchberger","year":"2016","unstructured":"Kirchberger MC, Hauschild A, Schuler G, et al. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma. Eur J Cancer. 2016;65:182\u20134.","journal-title":"Eur J Cancer"},{"key":"338_CR12","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2017.35.15_suppl.9508","volume":"35","author":"GV Long","year":"2017","unstructured":"Long GV, Atkinson V, Menzies AM, et al. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the anti-PD1 brain collaboration (ABC). J Clin Oncol. 2017;35:9508.","journal-title":"J Clin Oncol"},{"key":"338_CR13","unstructured":"Long GV AV, Menzies AM, et al., Randomized phase II study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): anti-PD-1 brain collaboration (ABC). Presented at: 2017 world congress of melanoma; October 18\u201321, 2017; Brisbane: Presentation SMR09\u20136.:"},{"key":"338_CR14","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","volume":"35","author":"HA-H Tawbi","year":"2017","unstructured":"Tawbi HA-H, Forsyth PAJ, Algazi AP, et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204. J Clin Oncol. 2017;35:9507.","journal-title":"J Clin Oncol"},{"key":"338_CR15","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/modpathol.2016.112","volume":"29","author":"AR Peck","year":"2016","unstructured":"Peck AR, Girondo MA, Liu C, et al. Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms. Mod Pathol. 2016;29:1143\u201354.","journal-title":"Mod Pathol"},{"key":"338_CR16","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1016\/j.ejca.2012.07.002","volume":"48","author":"M Preusser","year":"2012","unstructured":"Preusser M, Winkler F, Collette L, et al. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC brain metastases strategic meeting 2012. Eur J Cancer. 2012;48:3439\u201347.","journal-title":"Eur J Cancer"},{"key":"338_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/1748-717X-9-143","volume":"9","author":"MA Dyer","year":"2014","unstructured":"Dyer MA, Arvold ND, Chen YH, et al. The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiat Oncol. 2014;9:143.","journal-title":"Radiat Oncol"},{"key":"338_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0360-3016(95)00168-X","volume":"33","author":"TL Phillips","year":"1995","unstructured":"Phillips TL, Scott CB, Leibel SA, et al. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys. 1995;33:339\u201348.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"338_CR19","doi-asserted-by":"crossref","unstructured":"Tsao MN, Lloyd N, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2012;CD003869:1-75.","DOI":"10.1002\/14651858.CD003869.pub3"},{"key":"338_CR20","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamaoncol.2015.1206","volume":"1","author":"S Goyal","year":"2015","unstructured":"Goyal S, Silk AW, Tian S, et al. Clinical management of multiple melanoma brain metastases: a systematic review. JAMA Oncol. 2015;1:668\u201376.","journal-title":"JAMA Oncol"},{"key":"338_CR21","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925\u201331.","journal-title":"N Engl J Med"},{"key":"338_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijrobp.2012.03.017","volume":"85","author":"EF Stamell","year":"2013","unstructured":"Stamell EF, Wolchok JD, Gnjatic S, et al. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2013;85:293\u20135.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"338_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-015-0095-8","volume":"3","author":"JD Schoenfeld","year":"2015","unstructured":"Schoenfeld JD, Mahadevan A, Floyd SR, et al. Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer. 2015;3:50.","journal-title":"J Immunother Cancer"},{"key":"338_CR24","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15:5379\u201388.","journal-title":"Clin Cancer Res"},{"key":"338_CR25","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.14694\/EDBK_100005","volume":"35","author":"AS Berghoff","year":"2016","unstructured":"Berghoff AS, Venur VA, Preusser M, et al. Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book. 2016;35:e116\u201322.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"338_CR26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","volume":"92","author":"AP Kiess","year":"2015","unstructured":"Kiess AP, Wolchok JD, Barker CA, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving Ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92:368\u201375.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"338_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/1479-5876-9-204","volume":"9","author":"O Hamid","year":"2011","unstructured":"Hamid O, Schmidt H, Nissan A, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204.","journal-title":"J Transl Med"},{"key":"338_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207\u201311.","journal-title":"Science"},{"key":"338_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0207","volume":"3","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Lovly CM, Flavin M, et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res. 2015;3:288\u201395.","journal-title":"Cancer Immunol Res"},{"key":"338_CR30","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","volume":"34","author":"AI Daud","year":"2016","unstructured":"Daud AI, Wolchok JD, Robert C, et al. Programmed death-ligand 1 expression and response to the anti\u2013programmed death 1 antibody Pembrolizumab in melanoma. J Clin Oncol. 2016;34:4102\u20139.","journal-title":"J Clin Oncol"},{"key":"338_CR31","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in Cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"338_CR32","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet Oncol. 2014;384:1109\u201317.","journal-title":"Lancet Oncol"},{"key":"338_CR33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1126\/science.aaf2834","volume":"352","author":"CU Blank","year":"2016","unstructured":"Blank CU, Haanen JB, Ribas A, et al. The \u201ccancer immunogram\u201d. Science. 2016;352:658\u201360.","journal-title":"Science"},{"key":"338_CR34","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, et al. Oncolytic Virotherapy promotes Intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170:1109\u20131119 e10.","journal-title":"Cell"},{"key":"338_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/his.12537","volume":"66","author":"AS Berghoff","year":"2015","unstructured":"Berghoff AS, Ricken G, Widhalm G, et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology. 2015;66:289\u201399.","journal-title":"Histopathology"},{"key":"338_CR36","doi-asserted-by":"publisher","first-page":"e1057388","DOI":"10.1080\/2162402X.2015.1057388","volume":"5","author":"AS Berghoff","year":"2016","unstructured":"Berghoff AS, Fuchs E, Ricken G, et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology. 2016;5:e1057388.","journal-title":"Oncoimmunology"},{"key":"338_CR37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4161\/onci.20492","volume":"1","author":"L Martinet","year":"2012","unstructured":"Martinet L, Le Guellec S, Filleron T, et al. High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes. Oncoimmunology. 2012;1:829\u201339.","journal-title":"Oncoimmunology"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0338-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0338-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0338-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:43:25Z","timestamp":1601055805000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0338-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,6]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["338"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0338-6","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,6]]},"assertion":[{"value":"6 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from our patient to enroll on a bio-specimen collection protocol (linked to a DataBase Shared Resource (DBSR) protocol) approved by the Columbia University Institutional Review Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from patient\u2019s family for publication of patient history and images included in this submission as he is deceased at the time of authorship.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"25"}}